An immune biochip for SERS detection of tumor marker CYFRA21-1 and its preparation method
By designing the SERS detection immune biochip for CYFRA21-1, using the AuNRs@Ag probe and Fe3O4@GO immune substrate, high sensitivity and high selectivity detection of CYFRA21-1 are achieved, and the detection sensitivity in the prior art is solved The problem of low and insufficient accuracy, the detection concentration reaches pg level, meeting clinical needs.
Patent Information
- Application Number
- CN202310162019.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-24
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-02-24
AI Technical Summary
Existing detection methods cannot detect tumor markers such as lung cancer in an early and sensitive manner. Especially due to the high equipment cost and narrow linear range, it limits its application. It is difficult for traditional methods to distinguish CYFRA21-1 from structurally similar substances, which affects the Accuracy of detection.
A SERS detection immune biochip for tumor marker CYFRA21-1 was designed, using AuNRs@Ag labeled MB and modified CYFRA21-1A antibodies as SERS probes, combining surface-modified CYFRA21-1B antibodies and Fe3O4@GO immune substrate , realize specific identification and efficient detection of CYFRA21-1, and improve the sensitivity and selectivity of SERS.
High sensitivity and selective detection of CYFRA21-1 are achieved, the detection concentration reaches the pg level, significantly improving the sensitivity of the existing methods, and can show good concentrations with CYFRA21-1 within the range of 1pg/ml-10ng/ml. Linear relationship, meeting the requirements of clinical testing.
Smart Images

Figure CN116519935B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of tumor detection, and in particular relates to an immune biochip for SERS detection of a tumor marker CYFRA21-1 and a preparation method thereof. Background Art
[0002] Cancer is often asymptomatic in its early stages, and the concentration of tumor markers in biological samples is often extremely low. Existing electrochemical sensors are still not sensitive enough for early diagnosis. It is necessary to design and develop highly sensitive biosensing materials and devices to detect tumor markers early and identify precancerous lesions and pre-metastatic malignancies.
[0003] CYFRA21-1 is currently considered to be a tumor marker mainly used to detect lung cancer, especially for the diagnosis of non-small cell lung cancer (NSCLC). If there is an unclear annular shadow in the lungs and the serum CYFRA21-1 concentration is greater than 30ng / ml, the possibility of primary bronchial lung cancer is very high. The positive detection rate of various types of non-small cell lung cancer is 70% to 85%. The serum concentration level of CYFRA21-1 is positively correlated with the clinical stage of the tumor, and can also be used as an effective indicator for tracking early recurrence after lung cancer surgery and radiotherapy and chemotherapy. High serum concentration levels of CYFRA21-1 indicate that the disease is in the progressive stage and has a poor prognosis. The sign of quality success is a rapid decrease in the serum concentration of CYFRA21-1, otherwise it means that the lesion has not been completely cleared. If the serum level decreases and then increases, it indicates that the disease has recurred. However, a negative CYFRA21-1 cannot rule out the possibility of lung cancer. The sensitivity of CYFRA21-1 in diagnosing various types of lung cancer is as follows: squamous cell carcinoma > adenocarcinoma > large cell carcinoma > small cell carcinoma. In addition, CYFRA21-1 has a certain positive rate for other tumors, such as invasive bladder cancer, head and neck cancer, breast cancer, cervical cancer, and digestive tract cancer.
[0004] Currently, the traditional methods used to detect CYFRA21-1 mainly include enzyme-linked immunosorbent assay, flow fluorescence assay, fluorescence assay, surface plasmon resonance analysis, voltammetry and immunoradiometric assay. These methods are limited in application due to problems such as high equipment cost and narrow linear range.
[0005] Surface enhanced Raman scattering (SERS) is a vibrational spectroscopy technique that has been shown to be one of the most sensitive analytical methods for detecting disease biomarkers. SERS is based on enhanced Raman spectroscopy of precious metals such as silver or gold. Unlike traditional Raman spectroscopy, it has the characteristics of high sensitivity, strong chemical specificity, and narrow Raman spectral band. It can enhance the Raman signal by up to 10 4 -10 7amplitude, and high sensitivity for single molecule detection. SERS has been proven to be an ultra-sensitive and widely used detection method. Due to the unique properties of SERS, SERS has been used by many researchers for ultra-sensitive detection of tumor markers, especially for the detection of proteins and genes. At present, there are no literature reports on SERS detection of tumor marker CYFRA21-1. Summary of the invention
[0006] The purpose of the present invention is to provide an immune biochip for SERS detection of tumor marker CYFRA21-1 and a preparation method thereof. The chip prepared by the method has strong specificity, can specifically identify CYFRA21-1 adsorbed on a Fe3O4@GO immune substrate, can eliminate the interference of other substances with similar structures to CYFRA21-1, can be applied to the efficient and sensitive detection of CYFRA21-1, and improve the sensitivity and selectivity of SERS.
[0007] To achieve the above objectives, the present invention provides an immune biochip for SERS detection of tumor marker CYFRA21-1, the chip comprising a SERS probe located on an upper layer and an immune substrate located on a lower layer, the SERS probe is AuNRs@Ag labeled with MB and modified with CYFRA21-1A antibody, and the immune substrate is a Fe3O4@GO immune substrate surface-modified with CYFRA21-1B antibody and CYFRA21-1.
[0008] The present invention also provides a method for preparing the above-mentioned immune biochip for SERS detection of tumor marker CYFRA21-1, comprising the following steps:
[0009] (1) Preparation of SERS probe: AuNRs@Ag was labeled with MB, activated and then modified with CYFRA21-1A antibody to obtain the SERS probe;
[0010] (2) Preparation of Fe3O4@GO immune substrate: CYFRA21-1B antibody was modified on the Fe3O4@GO substrate, and then different concentrations of CYFRA21-1 were recognized to obtain Fe3O4@GO immune substrate;
[0011] (3) Preparation of immune biochip: The Fe3O4@GO immune substrate obtained in step (2) was immersed in the SERS probe obtained in step (1), incubated at room temperature for 2 h, and then the unconnected SERS probes were washed away with PBS at a concentration of 0.01 M to obtain an immune biochip for SERS detection of the tumor marker CYFRA21-1.
[0012] Furthermore, the specific steps of step (1) are as follows:
[0013] (1-1) 0.1 mL of 0.01 M MB solution was mixed with 0.9 mL of 2.36 mg / mL AuNRs@Ag solution, and the mixture was rotated at 250 rpm for 2 h, then centrifuged at 8000 rpm for 10 min and washed several times before being dispersed in 1 mL of 0.01 M PBS solution to obtain MB-labeled AuNRs@Ag nanorod dispersion;
[0014] (1-2) 50 μL of 100 mM EDC and 80 μL of 100 mM NHS were added to 1 mL of MB-labeled AuNRs@Ag nanorod dispersion, shaken at low speed for 30 min at room temperature, then washed twice with 0.01 M PBS, and then dispersed in 1 mL of 0.01 M PBS to obtain an activated MB-labeled AuNRs@Ag nanorod dispersion;
[0015] (1-3) Add 100 μL of 100 μg / mL anti-CYFRA21-1A to the activated MB-labeled AuNRs@Ag nanorod dispersion and incubate at 4°C for 12 h. Then add 50 μL of 3% BSA as a blocking agent and incubate at 4°C for 6 h. After centrifugation, disperse in 1 mL of 0.01 M PBS to obtain a SERS probe.
[0016] Furthermore, the preparation process of the AuNRs@Ag is as follows:
[0017] a. Mix 19.7 μL of 0.01M HAuCl4, 30.3 μL of deionized water and 2 mL of 0.1M CTAB to obtain a mixed solution, then quickly inject 0.12 mL of a newly prepared 0.378 mg / mL sodium borohydride solution into the mixed solution at 0°C, and the mixed solution quickly turns brown. Vortex the mixed solution in an ultrasonic water bath for 2 minutes, stir evenly, and place at 24-25°C for 2 hours to prepare a seed solution;
[0018] b. Place a 50 mL flask containing 40 mL of 36.45 mg / mL CTAC in a 30°C oil bath at 1200 rpm, and then add 400 μL of 0.01 M AgNO3, 788 μL of 0.01 M HAuCl4, 1.212 mL of deionized water, 0.8 mL of 1.0 M HCl, and 0.32 mL of 0.1 M AA to the flask in sequence to prepare a growth solution;
[0019] c. Inject 96 μL of the seed solution into the growth solution prepared in step b, stir for 30 seconds, grow for 2 hours, pour it into a centrifuge tube and centrifuge it at 8000 rpm for 10 minutes, discard the supernatant, and wash it 2 to 3 times with deionized water at the same speed and time. After the last centrifugation, AuNRs are obtained, which are dispersed with an ultrasonicator to obtain an AuNRs solution;
[0020] d. Add 0.08 M CTAC solution to the AuNRs solution prepared in step c, centrifuge at 8000 rpm for 10 minutes, remove the supernatant and centrifuge again in the same way to remove the supernatant once, and finally disperse in 12 ml of 0.08 M CTAC solution, then add 0.4 mL of 0.01 M AgNO3 and 0.32 mL of 0.1 M AA, mix thoroughly with an ultrasonic instrument for 2 min, incubate the solution in a 65 ° C water bath for 4.5 h, centrifuge at 8000 rpm for 20 min, wash twice with deionized water, disperse in 3 mL of water, adjust the final concentration to 2.36 mg / mL, and obtain AuNRs @ Ag solution.
[0021] Furthermore, the specific steps of step (2) are as follows:
[0022] 100 μL of 5 mg / mL magnetic graphene oxide dispersion was dispersed in 1 mL of 0.01 M PBS solution, and then 100 μL of 100 μg / mL CYFRA21-1B antibody was added, and incubated at 4°C for more than 12 h; 50 μL of 3% BSA was added as a blocking agent, and incubated at 4°C for 6 h. Finally, the immune Fe3O4@GO substrate was collected by magnetic separation and resuspended in 1 mL of 0.01 M PBS; 100 μL of the immune Fe3O4@GO substrate was dropped into a 2 mL centrifuge tube, and then 40 μL of CYFRA21-1 standard solution of different concentrations was added to the centrifuge tube. After incubation at room temperature for 3 h, the mixture was magnetically separated and washed with PBS to obtain the Fe3O4@GO immune substrate.
[0023] Compared with the prior art, the present invention has the following advantages:
[0024] (1) The chip prepared by the present invention has strong specificity and can specifically identify CYFRA21-1 adsorbed on the Fe3O4@GO immune substrate, and can eliminate the interference of other substances with similar structures to CYFRA21-1. It can be applied to the efficient and sensitive detection of CYFRA21-1, thereby improving the sensitivity and selectivity of SERS.
[0025] (2) The present invention establishes a method for detecting CYFRA21-1 with high sensitivity and selectivity, which can meet the requirements of sensitivity and specificity in the method validation process. At present, the main clinical method for detecting CYFRA21-1 is chemiluminescence, and its detection concentration is only at the ng level, while the detection concentration of the present invention reaches the pg level, which is several orders of magnitude higher, which greatly improves the defect of low sensitivity of the existing method.
[0026] (3) In the present invention, gold and silver nanorods with higher Raman signals were selected as probes, and magnetic graphene oxide was selected as the magnetic substrate. The linear relationship between the Raman peak intensity and the logarithm of the CYFRA21-1 concentration was wider. In the range of 1pg / ml-10ng / ml, CYFRA21-1 had a good linear relationship. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 It is a schematic diagram of the detection principle of the present invention;
[0028] Figure 2 The SEM images of AuNRs nanorods and AuNRs@Ag in Example 1; (A) AuNRs nanorods; (B) AuNRs@Ag;
[0029] Figure 3 The Raman spectra of MB on AuNRs and AuNRs@Ag at the same concentration in Example 1;
[0030] Figure 4 The UV-visible spectra of AuNRs and AuNRs@Ag in Example 1;
[0031] Figure 5 The Raman spectra of AuNRs@Ag nanoprobes at different MB concentrations in Example 1;
[0032] Figure 6 TEM images of the Fe3O4@GO immune substrate in Example 1, (A), the scale is 100nm, (B), the scale is 200nm;
[0033] Figure 7 The Raman spectra of the specific antibodies in different volumes (10-100 μL) in Example 1;
[0034] Figure 8 The Raman spectra of the probes with different dosages (25-400 μL) in Example 1;
[0035] Fig. 9 This is a schematic diagram of the specificity test results of the SERS dual antibody system for CYFRA21-1 antigen in Example 2;
[0036] Fig.10 The SERS spectra of CYFRA21-1 at different concentrations in Example 3;
[0037] Fig.11 CYFRA21-1 (1 pg mL -1 -10ng mL -1 ) Standard curve of concentration Lg value and SERS intensity at the peak of 448 cm-1;
[0038] Fig.12 The SERS spectra of human serum at different dilution multiples in Example 4;
[0039] Fig.13 This is a linear relationship diagram between the SERS signal of human serum at different dilution multiples and the CYFRA21-1 concentration in Example 4. DETAILED DESCRIPTION
[0040] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0041] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the present technical field.
[0042] In the following embodiments:
[0043] CYFRA21-1A antibody is a capture antibody with a concentration of 4.1 mg / ml; CYFRA21-1B antibody is a detection antibody with a concentration of 8.9 mg / ml, produced by Holmes Company.
[0044] CYFRA21-1, CA199, CA125, NSE, and CEA were all obtained from the calibration fluid of the Laboratory Department of the East Hospital of the Affiliated Hospital of Xuzhou Medical University.
[0045] Magnetic graphene oxide dispersion was purchased from Jiangsu Xianfeng Nanomaterial Technology Co., Ltd.
[0046] Embodiment 1
[0047] A method for preparing an immune biochip for SERS detection of a tumor marker CYFRA21-1 comprises the following steps:
[0048] (1) Preparation of SERS probe: AuNRs@Ag was labeled with MB, activated and then modified with CYFRA21-1A antibody to obtain the SERS probe;
[0049] The specific preparation process is:
[0050] (1-1) 0.1 mL of 0.01 M MB solution was mixed with 0.9 mL of 2.36 mg / mL AuNRs@Ag solution, and the mixture was rotated at 250 rpm for 2 h, then centrifuged at 8000 rpm for 10 min and washed several times before being dispersed in 1 mL of 0.01 M PBS solution to obtain MB-labeled AuNRs@Ag nanorod dispersion;
[0051] (1-2) 50 μL of 100 mM EDC and 80 μL of 100 mM NHS were added to 1 mL of MB-labeled AuNRs@Ag nanorod dispersion, shaken at low speed for 30 min at room temperature, then washed twice with 0.01 M PBS, and then dispersed in 1 mL of 0.01 M PBS to obtain an activated MB-labeled AuNRs@Ag nanorod dispersion;
[0052] (1-3) Add 100 μL of 100 μg / mL anti-CYFRA21-1A to the activated MB-labeled AuNRs@Ag nanorod dispersion and incubate at 4°C for 12 h. Then add 50 μL of 3% BSA (i.e., 3 g of bovine serum albumin completely dissolved in 100 mL of PBS solution) as a blocking agent to prevent nonspecific absorption of the antigen. Incubate at 4°C for 6 h. After centrifugation, disperse in 1 mL of 0.01 M PBS to obtain a SERS probe.
[0053] The preparation process of the AuNRs@Ag solution is as follows:
[0054] a. Mix 19.7 μL of 0.01M HAuCl4, 30.3 μL of deionized water and 2 mL of 0.1M CTAB to obtain a mixed solution, then quickly inject 0.12 mL of a newly prepared 0.378 mg / mL sodium borohydride solution into the mixed solution at 0°C, and the mixed solution quickly turns brown. Vortex the mixed solution in an ultrasonic water bath for 2 minutes, stir evenly, and place at 24-25°C for 2 hours to prepare a seed solution;
[0055] b. Place a 50 mL flask containing 40 mL of 36.45 mg / mL CTAC in a 30°C oil bath at 1200 rpm, and then sequentially add 400 μL of 0.01 M AgNO3, 788 μL of 0.01 M HAuCl4, 1.212 mL of deionized water, 0.8 mL of 1.0 M HCl, and 0.32 mL of 0.1 M AA (ascorbic acid) to the flask to prepare a growth solution;
[0056] c. Inject 96 μL of the seed solution into the growth solution prepared in step b, stir for 30 seconds, grow for 2 hours, pour it into a centrifuge tube and centrifuge it at 8000 rpm for 10 minutes, discard the supernatant, and wash it 2 to 3 times with deionized water at the same speed and time. After the last centrifugation, leave 1 ml of AuNRs, disperse it with an ultrasonicator to obtain an AuNRs solution;
[0057] d. Prepare an appropriate amount of 0.08M CTAC solution, add it to the AuNRs solution prepared in step c, centrifuge at 8000rpm for 10 minutes, remove the supernatant and centrifuge again in the same way to remove the supernatant once, finally disperse in 12ml 0.08M CTAC solution, then add 0.4mL of 0.01M AgNO3 and 0.32mL of 0.1M AA (ascorbic acid), mix thoroughly with an ultrasonic instrument for 2min, incubate the solution in a 65℃ water bath for 4.5h, centrifuge at 8000rpm for 20min, wash twice with deionized water, disperse in 3mL of water, adjust the final concentration to 2.36mg / mL, and obtain AuNRs@Ag solution.
[0058] The characterization analysis of the bimetallic nanorods is as follows:
[0059] from Figure 2 A and Figure 2 B It can be clearly observed that the surface of the gold nanorods is covered with a layer of silver. When the concentrations of AuNRs@Ag and AuNRs are the same, the ratio of AuNRs@Ag and AuNRs@Ag measured at a ratio of 9:1 is 1:1. -2 The Raman intensity of MMB is significantly higher than that of pristine AuNRs ( Figure 3 The SERS effect of bimetallic nanorods is much stronger than that of single metal nanorods. This is because there are extremely strong electromagnetic fields at both ends of the bimetallic nanorods ( Figure 3 ). The electromagnetic enhancement of the inter-interval coupling creates more "hot spots" in the internal gap, thereby inducing a stronger SERS signal, which Nikoobakht et al. attributed to the lightning rod effect at both ends of the rod. It can be inferred that the synergistic effect between Au and Ag contributes greatly to the enhancement, as shown in the UV-visible spectra of the two nanoprobes ( Figure 4 ) showed that the bimetallic nanorods AuNRs@Ag had a gold nanorod-specific peak at around 900nm and a silver nanorod-specific peak at around 650nm. These results indicate that the construction of AuNRs@Ag was successful.
[0060] The optimization process of MB concentration is as follows: using the prepared AuNRs@Ag nanorods to further optimize the MB concentration, mixing MB solutions of different concentrations (10 -9 M-10 -1M) was added to the AuNRs@Ag solution at a ratio of 9:1, and the Raman intensity was measured. Figure 5 It can be seen that when the MB concentration is reduced to 10 -9 When the concentration of MB is 10 -2 The Raman intensity is the highest when the concentration of MB is 10. -2 M was used as the optimal concentration for subsequent SERS detection. Subsequently, in order to further quantify the SERS activity, the Raman enhancement factor (EF) of AuNRs@Ag was calculated. By comparing the MB (448 cm -1 ) and the SERS intensity of MB (448 cm -1 ) in 10 -3 EF is estimated by the Raman intensity at mol / L. The EFs of MB are calculated in the range of 1.34×10-2.15×10 7 , indicating that the probe has a high detection sensitivity for low-concentration molecules.
[0061] (2) Preparation of Fe3O4@GO immunogenic substrate:
[0062] 100 μL of 5 mg / mL magnetic graphene oxide dispersion was dispersed in 1 mL of 0.01 M PBS solution, and then 100 μL of 100 μg / mL CYFRA21-1B antibody was added, and incubated at 4°C for more than 12 h; then 50 μL of 3% BSA (i.e., 3 g of bovine serum albumin was completely dissolved in 100 mL of PBS solution) was added as a blocking agent, and incubated at 4°C for 6 h. Finally, the immune Fe3O4@GO substrate was collected by magnetic separation and resuspended in 1 mL of 0.01 M PBS;
[0063] 100 μL of immune Fe3O4@GO substrate was dropped into a 2 mL centrifuge tube, and then 40 μL of CYFRA21-1 standard solution of different concentrations was added to the centrifuge tube. After incubation at room temperature for 3 h, the mixture was magnetically separated and washed with PBS to remove unbound antigens to obtain Fe3O4@GO immune substrate. Figure 6 It can be seen that the layered structure of the gray flakes is graphene oxide, and the black particles supported on it are Fe3O4, indicating that the Fe3O4@GO immune substrate was successfully prepared.
[0064] Through further optimization, the optimal dosage of immune Fe3O4@GO substrate and the optimization of immune conditions were determined. Figure 7 and Figure 8The Raman spectra of different concentrations of immune-Fe3O4@GO substrate and antibody-coupled immune probe added to the SERS platform. As the amount of immune-Fe3O4@GO substrate increased from 10μL to 100μL, the Raman signal gradually increased. The increase in Raman signal intensity may be due to antigen-antibody binding. There is little difference in Raman signal when 50μL and 100μL of immune-Fe3O4@GO substrate are added ( Figure 7 ). Similarly, as the probe volume increases from 25 μL to 400 μL, the Raman intensity gradually increases ( Figure 8 ); however, when the probe volume increased from 200 μL to 400 μL, the Raman signal did not change, which may be related to the saturation of the substrate or the probe. Based on this, the optimal volumes of the substrate and probe are 100 μL and 200 μL, respectively.
[0065] (3) Preparation of immune biochip: 100 μL Fe3O4@GO immune substrate obtained in step (2) was immersed in 200 μL SERS probe obtained in step (1), incubated at room temperature for 2 h, then washed away the unattached SERS probe with 0.01 M PBS, and finally the precipitate was dispersed in 200 μL deionized water to obtain an immune biochip for SERS detection of tumor marker CYFRA21-1. The detection principle is as follows: Figure 1 shown.
[0066] Embodiment 2
[0067] Specificity testing of SERS immunoassays
[0068] The specificity of SERS immunoassay was tested by adding different antigens to the SERS immunoassay platform. When 40 μL of CYFRA21-1 (100 pg / mL), CA199 (281 U / mL), CA125 (281 U / mL), NSE (50.5 ng / mL), and CEA (100 ng / mL) were added to the immunoassay reaction system ( Fig. 9 ), only the Raman signal of CYFRA21-1 protein was strong, while the Raman signals of other antigen proteins were very weak, indicating that the immunoassay system was specific to CYFRA21-1.
[0069] Embodiment 3
[0070] Linearity of SERS immunoassay
[0071] The proposed SERS-based immunoassay was tested using different concentrations of CYFRA21-1. The SERS spectra of the SERS immunoassay reaction with different concentrations of CYFRA21-1 had three strong Raman peaks (448 cm -1 、1441cm-1 and 1626cm -1 )( Fig.10 ). Using MB at 448cm -1 The SERS intensity at the target antigen was quantitatively evaluated ( Fig.10 ). In the absence of CYFRA21-1, no obvious SERS signal was detected, indicating that the washing process can remove almost all unreacted probes. As the concentration of target antigen increases, the SERS signal increases. In addition, as the antigen is diluted, the SERS intensity decreases. When the concentration of CYFRA21-1 is reduced to 1 pg mL -1 MB at 448cm -1 The SERS peak at CYFRA21-1 (1pg mL -1 -10ng mL -1 ) The standard curve of the concentration lg value and SERS intensity at the peak of 448cm-1 is as follows Fig.11 The corresponding linear equation is int = 5657 [Lg [CYFRA21-1]] + 5055 (correlation coefficient R 2 =0.9916, N=3). According to the 3σ rule (σ is the standard deviation), the detection limit of 10 blank samples was estimated to be 0.8943 pg mL -1 These results indicate that the SERS-based sandwich immunoassay has a good linear relationship.
[0072] Embodiment 4
[0073] Validation of SERS immunoassay in human serum samples
[0074] In order to verify the potential diagnostic value of the immunoassay method, the SERS method and chemiluminescence method proposed in the present invention were used to detect CYFRA21-1 in three clinical serum samples. The concentration of CYFRA21-1 determined by the SERS immunoassay was consistent with that determined by the chemiluminescence method, and the coefficient of variation (CV) was acceptable within the clinically acceptable range. One of the serum samples was diluted to 10 times, 100 times, and 1000 times with PBS solution, and the SERS signal ( Fig.12 and Table 1), the SERS signal was linearly related to the CYFRA21-1 concentration ( Fig.13 The concentration of the target protein in serum was calculated by the standard linear equation (Table 1). In human serum samples, the minimum detection amount of CYFRA21-1 by SERS immunoassay was 6.68 pg mL -1 Therefore, the SERS-based detection technique has the potential to be applied in the clinical detection of CYFRA21-1 in human serum.
[0075] Table 1 Calculation of protein content in diluted serum samples
[0076]
[0077] Embodiment 5
[0078] Method comparison: SERS immunoassay versus other CYFRA21-1 detection methods
[0079]
[0080] Table 2. Comparison of SERS immunoassay with other CYFRA21-1 detection methods.
[0081] As shown in Table 2, compared with these traditional methods, surface enhanced Raman spectroscopy (SERS) has many significant advantages, including higher selectivity, higher sensitivity and other excellent properties.
Claims
1. An immune biochip for SERS detection of tumor marker CYFRA21-1, characterized in that: The chip comprises a SERS probe located on an upper layer and an immune substrate located on a lower layer, wherein the SERS probe is AuNRs@Ag labeled with MB and modified with CYFRA21-1A antibody, and the immune substrate is a Fe3O4@GO immune substrate with surface modified with CYFRA21-1B antibody and CYFRA21-1; the preparation method of the immune biochip comprises the following steps: (1) Preparation of SERS probe: AuNRs@Ag was labeled with MB, activated and then modified with CYFRA21-1A antibody to obtain the SERS probe; the specific steps are as follows: 0.1 mL of 0.01 M MB solution was mixed with 0.9 mL of 2.36 mg / mL AuNRs@Ag solution, rotated at 250 rpm for 2 h, then centrifuged at 8000 rpm for 10 min and washed several times before being dispersed in 1 mL of 0.01 M PBS solution to obtain MB-labeled AuNRs@Ag nanorod dispersion; 50 μL of 100 mM EDC and 80 μL of 100 mM NHS were added to 1 mL of MB-labeled AuNRs@Ag nanorod dispersion, shaken at low speed for 30 min at room temperature, then washed twice with 0.01 M PBS, and then dispersed in 1 mL of 0.01 M PBS to obtain an activated MB-labeled AuNRs@Ag nanorod dispersion; 100 μL of 100 μg / mL anti-CYFRA21-1A was added to the activated MB-labeled AuNRs@Ag nanorod dispersion, and the mixture was incubated at 4°C for 12 h. Then, 50 μL of 3% BSA was added as a blocking agent, and the mixture was incubated at 4°C for 6 h. After centrifugation, the mixture was dispersed in 1 mL of 0.01 M PBS to obtain a SERS probe. (2) Preparation of Fe3O4@GO immune substrate: CYFRA21-1B antibody was modified on the Fe3O4@GO substrate, and then different concentrations of CYFRA21-1 were recognized to obtain the Fe3O4@GO immune substrate; the specific steps are as follows: 100 μL of 5 mg / mL magnetic graphene oxide dispersion was dispersed in 1 mL of 0.01M PBS solution, and then 100µL of 100µg / mL CYFRA21-1B antibody was added, and incubated at 4°C for more than 12h; 50 μL of 3% BSA was added as a blocking agent, and incubated at 4°C for 6h. Finally, the immune Fe3O4@GO substrate was collected by magnetic separation and resuspended in 1mL of 0.01M PBS; 100µL of immune Fe3O4@GO substrate was dropped into a 2 mL centrifuge tube, and then 40µL of CYFRA21-1 standard solution of different concentrations was added to the centrifuge tube. After incubation at room temperature for 3h, the mixture was magnetically separated and washed with PBS to obtain Fe3O4@GO immune substrate; (3) Preparation of immune biochip: The Fe3O4@GO immune substrate obtained in step (2) was immersed in the SERS probe obtained in step (1), incubated at room temperature for 2 h, and then the unconnected SERS probes were washed away with PBS at a concentration of 0.01 M to obtain an immune biochip for SERS detection of the tumor marker CYFRA21-1.
2. The immune biochip for SERS detection of tumor marker CYFRA21-1 according to claim 1, characterized in that: The preparation process of AuNRs@Ag is as follows: a. Mix 19.7 μL of 0.01 M HAuCl4, 30.3 μL of deionized water and 2 mL of 0.1 M CTAB to obtain a mixed solution. Then, quickly inject 0.12 mL of a newly prepared 0.378 mg / mL sodium borohydride solution into the mixed solution at 0°C. The mixed solution quickly turns brown. Vortex the mixed solution in an ultrasonic water bath for 2 minutes, stir evenly, and place it at 24-25°C for 2 hours to prepare a seed solution. b. Place a 50 mL flask containing 40 mL of 36.45 mg / mL CTAC in a 30°C oil bath at 1200 rpm, then add 400 μL of 0.01 M AgNO3, 788 μL of 0.01 M HAuCl4, 1.212 mL of deionized water, 0.8 mL of 1.0 M HCl, and 0.32 mL of 0.1 M AA to the flask to prepare a growth solution; c. Inject 96 µL of the seed solution into the growth solution prepared in step b, stir for 30 seconds, grow for 2 hours, pour it into a centrifuge tube and centrifuge it at 8000 rpm for 10 minutes, discard the supernatant, and wash it with deionized water at the same speed and time for 2 to 3 times. After the last centrifugation, AuNRs are obtained, which are dispersed with an ultrasonicator to obtain an AuNRs solution; d. Add 0.08 M CTAC solution to the AuNRs solution prepared in step c, centrifuge at 8000 rpm for 10 minutes, remove the supernatant and centrifuge again in the same way to remove the supernatant once, finally disperse in 12 ml 0.08 M CTAC solution, then add 0.4 mL of 0.01 M AgNO3 and 0.32 mL of 0.1 M AA, mix thoroughly with an ultrasonic instrument for 2 minutes, incubate the solution in a 65 ° C water bath for 4.5 hours, centrifuge at 8000 rpm for 20 minutes, wash twice with deionized water, disperse in 3 mL of water, adjust the final concentration to 2.36 mg / mL, and obtain AuNRs@Ag solution.
Citation Information
Patent Citations
Method for detecting pathogens with sandwich structure through SERS
CN108872194A
Preparation and application based on composite magnetic SERS platform
CN112326627A
Graphene Oxide induced Metallic Nanoparticle Clustering for Surface Enhanced Raman Scattering-based Biosensing and / or Bioimaging
KR1020150101400A
